REVEALing where we stand with HDL
Dr. Christopher Cannon explains the CV benefits of CETP inhibition in relation to non-HDL-c reduction
Video navigation menu
- Is HDL-c simply a marker of increased CV risk? 00:18
- Effect of niacin 00:42
- CETP inhibition: Primary outcome of REVEAL 01:08
- Benefit vs reduction in non-HDL-c 02:01
- Management of low HDL-c 04:25
This video was recorded on October 26, 2017 in Boston and is a shortened version of the presentation that Dr. Cannon gave there during the educational program 'Advances in Lipid Management and Cardiovascular Risk Reduction: New Horizons for 2018'
Dr. Christopher Paul Cannon is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH) and a professor of medicine at Harvard Medical School (HMS). Dr. Cannon is the executive director of cardiometabolic trials at the Harvard Clinical Research Institute.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this recording.
Share this page with your colleagues and friends: